Table 7. Studies of IORT in various paediatric tumours.
| Author/Year | Sample size | Study design | IORT type | IORT dose (Gy) | EBRT % | Median Follow-up | LC 5 year (%) | OS 5 year (%) | Toxicity grade 3 or > |
|---|---|---|---|---|---|---|---|---|---|
| Haase et al [102] 1994 | 25 (neuroblastoma) | Prospective, single arm | IOERT | 10–17 | NR | 51 (mean) | 75 | 63 | No late effects at 5-year follow-up |
| Nag et al [106] 2003 | 13 (5 metastatic) | Retrospective | IOERT | 10–15 | 38 | 42 | 72 (3yr) |
31 (3yr) |
late morbidity-30% |
| Goodman et al [104] 2003 | 66 (35% recurrent) | Retrospective | HDR-IORT | 12–15 | 44 | 12 | 56 (2yr) |
54 (2yr) |
Late morbidity-12% |
| Oertel et al [103] 2005 |
18 (17% recurrent) | Retrospective | IOERT | 8–15 | 100 | 54.5 | 95 (3yr) |
83 (3yr) |
late morbidity-33% Loss of Limb-1* Neuropathy-1* |
| Stauder et al [107] 2011 | 20 | Retrospective | IOERT | 7.5–25 | 100 | 139 | 77 (10yr) |
65 (10yr) |
No grade 3 or more late effects or second primary |
| Sole et al [105] 2015 | 71 (35% recurrent) | Retrospective | IOERT | 7.5–20 | 100 | 72 | 68 (10yr) |
74 (10yr) |
Late morbidity-13% Neuropathy-4* Necrosis-2* Lymphedema-2* |
LC: local control, OS: overall survival, DFS: disease-free survival, NR: not reported,
*
Number of patients.